Evidence map›Paper›PMID 38137624›Full record

ReviewJournal of clinical medicine2023

Predictive Factors of Response to Streptozotocin in Neuroendocrine Pancreatic Neoplasms.

Giuseppe Fanciulli, Anna La Salvia, Sergio Di Molfetta, Giuseppe Cannavale, Giulia Puliani, Monica Verrico, Federica Campolo, Annamaria Colao, Antongiulio Faggiano, Nike Group

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of clinical medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 1 country.

Giuseppe FanciulliEndocrine Oncology Program, Endocrine Unit, Department of Medical, Surgical and Experimental Sciences, University of Sassari, University Hospital of Sassari, 07100 Sassari, Italy.ORCID 0000-0002-8367-5649
Anna La SalviaNational Center for Drug Research and Evaluation, National Institute of Health (ISS), 00161 Rome, Italy.ORCID 0000-0002-5020-8657
Sergio Di MolfettaSection of Internal Medicine, Endocrinology, Andrology and Metabolic Diseases, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari Aldo Moro, 70124 Bari, Italy.
Giuseppe CannavaleUnit of Endocrinology, Andrology, Diabetology and Nutrition, Department of Clinical Medicine and Surgery, Federico II University, 80131 Naples, Italy.
Giulia PulianiOncological Endocrinology Unit, Regina Elena National Cancer Institute IRCCS, 00144 Rome, Italy.ORCID 0000-0003-2899-9146
Monica VerricoDepartment of Radiology, Oncology and Pathology, Sapienza University of Rome, 00161 Rome, Italy.
Federica CampoloDepartment of Experimental Medicine, Sapienza University of Rome, 00161 Rome, Italy.ORCID 0000-0002-9290-874X
Annamaria ColaoUNESCO Chair, Education for Health and Sustainable Development, Federico II University, 80131 Naples, Italy.
Antongiulio FaggianoEndocrinology Unit, Department of Clinical and Molecular Medicine, The European Neuroendocrine Tumor Society (ENETS) Center of Excellence, Sant'Andrea Hospital, Sapienza University of Rome, 00189 Rome, Italy.ORCID 0000-0002-9324-3946
Nike Group
Sapienza University of Rome · ITFederico II University Hospital · ITIstituti di Ricovero e Cura a Carattere Scientifico · ITIstituto Superiore di Sanità · ITUniversity of Bari Aldo Moro · ITUniversity of Sassari · IT

Funding

Italian Ministry of Education, University and Research (MIUR) PRIN 2017Z3N3YC
6 · The paper itself

Abstract

Pancreatic neuroendocrine neoplasms (Pan-NENs) may exhibit a heterogeneous clinical course, ranging from indolent to progressive/metastatic behavior. In the latter scenario, streptozocin (STZ) is considered the cornerstone of systemic treatment; however, response to STZ-based chemotherapy may vary among individuals. In this narrative review, we aimed to identify the predictive factors of response to STZ in advanced Pan-NENs. We performed an extensive search in international online databases for published studies and ongoing clinical trials evaluating STZ in Pan-NENs. We found 11 pertinent studies evaluating 17 patient-, tumor-, or treatment-related factors. Age, CgA blood levels, tumor grade, Ki-67% index, anatomical location of the primary tumor, tumor stage, site of metastasis origin, liver tumor burden, extrahepatic spread, functional status, O6-methylguanine-methyltransferase (MGMT) status, line of therapy, and response to previous treatments were all statistically associated with radiological response and/or survival. The identified predictors may help clinicians make appropriate treatment decisions, in this way improving clinical outcomes in patients with advanced Pan-NENs.

Indexed as

neuroendocrine pancreatic neoplasmpredictors of responsestreptozotocin

Identifiers

PMID38137624
PMCPMC10743702
OpenAlexW4389438556

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.